摘要
目的多索茶碱和茶碱缓释片治疗慢性阻塞性肺炎(COPD)的临床疗效及安全性。方法研究自医院抽取158例入院治疗COPD患者,时间为2019年1月-2019年12月,按照患者治疗中用药的不同分为人数均等的两组(n=79),其中实施茶碱缓释片为对照组,实施多索茶碱为观察组,评估两组患者疗效、肺功能指标、不良反应并对比。结果疗效比较:与对照组相比,观察组疗效偏高,两组患者对比有统计学差异(P<0.05)。各项肺功能指标比较:治疗前,两组指标差异小(P>0.05),与对照组相比,观察组各指标偏高,两组患者对比有统计学差异(P<0.05)。血气分析变化比较:治疗前,两组指标差异小(P>0.05),与对照组相比,观察组各指标更优,两组患者对比有统计学差异(P<0.05)。不良反应比较:与对照组相比,观察组不良反应偏低,两组患者对比有统计学差异(P<0.05)。结论对COPD患者使用多索茶碱治疗比茶碱缓释片疗效更高,能够优化肺功能指标,减少临床不良反应,预后良好。
Objective To evaluate the clinical efficacy and safety of Doxofylline and Theophylline Sustained Release Tablets in the treatment of Chronic Obstructive Pneumonia(COPD).Methods One hundred and fifty-eight patients with COPD were selected from the hospital from January 2019 to December 2019.They were divided into two equal groups(n=79)according to the different drugs used in the treatment.The Theophylline Sustained Release Tablets were used as the control group,and Doxofylline was used as the observation group.The curative effect,pulmonary function index and adverse reactions of the two groups were evaluated and compared.Results Curative effect comparison:Compared with the control group,the curative effect of the observation group was higher,and there was a statistical difference between the two groups(P<0.05).Comparison of various pulmonary function indexes:Before treatment,the differences between the two groups were small(P>0.05),compared with the control group,the indexes in the observation group were higher,and there was statistical difference between the two groups(P<0.05).Comparison of blood gas analysis changes:Before treatment,there was little difference between the two groups(P>0.05).Compared with the control group,the indexes in the observation group were better,and there was statistical difference between the two groups(P<0.05).Comparison of adverse reactions:Compared with the control group,the adverse reactions in the observation group were lower,and there was statistical difference between the two groups(P<0.05).Conclusion Doxofylline is more effective than Theophylline Sustained Release Tablets in the treatment of COPD patients,which can optimize lung function indexes,reduce clinical adverse reactions and have a good prognosis.
作者
邹秋亚
ZOU Qiu-ya(The First People’s Hospital of Changzhou,Changzhou,Jiangsu 213100)
出处
《智慧健康》
2021年第32期116-118,共3页
Smart Healthcare
关键词
多索茶碱
茶碱缓释片
慢性阻塞性肺炎
Doxofylline
Theophylline Sustained Release Tablets
Chronic Obstructive Pneumonia
